[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100657920":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":13,"studyPopulation":13,"armGroups":20,"interventions":27,"overallOfficials":13,"centralContacts":33,"locations":41,"responsibleParty":188,"collaborators":13,"id":190,"slug":191,"hasResults":192,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":13,"eligibilityCriteria":196,"healthyVolunteers":192,"sex":197,"minAge":198,"maxAge":199,"enrollmentInfo":200,"targetDuration":13,"studyType":203,"phases":204,"briefSummary":206,"conditions":207,"keywords":13,"overallStatus":44,"whyStopped":13,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":218},{"fullName":5,"class":6},"Adneuris Therapeutics, Inc.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Sum of pain intensity differences through 48 hours (SPID48)","Sum of pain intensity differences through 48 hours (SPID48), calculated from NPRS assessments collected following the first administration of cebranopadol.","From 0 through 48 hours",null,{"allocation":15,"interventionModel":16,"interventionModelDescription":13,"primaryPurpose":17,"observationalModel":13,"timePerspective":13,"maskingInfo":18},"NA","SINGLE_GROUP","TREATMENT",{"masking":19,"maskingDescription":13,"whoMasked":13},"NONE",[21],{"label":22,"type":23,"description":24,"interventionNames":25},"Cebranopadol","EXPERIMENTAL","Participants receive Cebranopadol 400 µg Starting dose 400 mcg once per day for 14 days or until pain resolves, whichever occurs first.",[26],"Drug: Cebranopadol 400 ug",[28],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":13},"DRUG","Cebranopadol 400 ug","Participants receive Cebranopadol 400 mcg once per day for 14 days or until pain resolves, whichever occurs first.",[22],[34,39],{"name":35,"role":36,"phone":37,"phoneExt":13,"email":38},"Study Director, Adneuris Therapeutics","CONTACT","732-940-2800","clinicaltrials@trispharma.com",{"name":40,"role":36,"phone":37,"phoneExt":13,"email":38},"Emilio Quetglas, MD",[42,56,66,76,86,97,107,117,127,137,146,155,164,173,178],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":13},"Adneuris Site 001115","RECRUITING","Phoenix","Arizona","85053","United States","US",{"type":51,"coordinates":52},"Point",[53,54],-112.07404,33.44838,{"lat":54,"lon":53},{"facility":57,"status":44,"city":58,"state":59,"zip":60,"country":48,"countryCode":49,"cosmosGeoPoint":61,"geoPoint":65,"contacts":13},"Adneuris Site 001118","Riverside","California","92504",{"type":51,"coordinates":62},[63,64],-117.39616,33.95335,{"lat":64,"lon":63},{"facility":67,"status":44,"city":68,"state":69,"zip":70,"country":48,"countryCode":49,"cosmosGeoPoint":71,"geoPoint":75,"contacts":13},"Adneuris Site 001119","Longmont","Colorado","80501",{"type":51,"coordinates":72},[73,74],-105.10193,40.16721,{"lat":74,"lon":73},{"facility":77,"status":44,"city":78,"state":79,"zip":80,"country":48,"countryCode":49,"cosmosGeoPoint":81,"geoPoint":85,"contacts":13},"Adneuris Site 001122","Savannah","Georgia","31406",{"type":51,"coordinates":82},[83,84],-81.09983,32.08354,{"lat":84,"lon":83},{"facility":87,"status":88,"city":89,"state":90,"zip":91,"country":48,"countryCode":49,"cosmosGeoPoint":92,"geoPoint":96,"contacts":13},"Adneuris Site 001123","NOT_YET_RECRUITING","O'Fallon","Illinois","62269",{"type":51,"coordinates":93},[94,95],-89.91121,38.59227,{"lat":95,"lon":94},{"facility":98,"status":44,"city":99,"state":100,"zip":101,"country":48,"countryCode":49,"cosmosGeoPoint":102,"geoPoint":106,"contacts":13},"Adneuris Site 001125","Annapolis","Maryland","21401",{"type":51,"coordinates":103},[104,105],-76.49184,38.97859,{"lat":105,"lon":104},{"facility":108,"status":44,"city":109,"state":110,"zip":111,"country":48,"countryCode":49,"cosmosGeoPoint":112,"geoPoint":116,"contacts":13},"Adneuris Site 001120","Oradell","New Jersey","07649",{"type":51,"coordinates":113},[114,115],-74.03681,40.95871,{"lat":115,"lon":114},{"facility":118,"status":44,"city":119,"state":120,"zip":121,"country":48,"countryCode":49,"cosmosGeoPoint":122,"geoPoint":126,"contacts":13},"Adneuris Site 001124","Tulsa","Oklahoma","74137",{"type":51,"coordinates":123},[124,125],-95.99277,36.15398,{"lat":125,"lon":124},{"facility":128,"status":44,"city":129,"state":130,"zip":131,"country":48,"countryCode":49,"cosmosGeoPoint":132,"geoPoint":136,"contacts":13},"Adneuris Site 001110","Bellaire","Texas","77401",{"type":51,"coordinates":133},[134,135],-95.45883,29.70579,{"lat":135,"lon":134},{"facility":138,"status":44,"city":139,"state":130,"zip":140,"country":48,"countryCode":49,"cosmosGeoPoint":141,"geoPoint":145,"contacts":13},"Adneuris Site 001117","Forney","75126",{"type":51,"coordinates":142},[143,144],-96.47193,32.74818,{"lat":144,"lon":143},{"facility":147,"status":44,"city":148,"state":130,"zip":149,"country":48,"countryCode":49,"cosmosGeoPoint":150,"geoPoint":154,"contacts":13},"Adneuris Site 001104","McAllen","78501",{"type":51,"coordinates":151},[152,153],-98.23001,26.20341,{"lat":153,"lon":152},{"facility":156,"status":88,"city":157,"state":130,"zip":158,"country":48,"countryCode":49,"cosmosGeoPoint":159,"geoPoint":163,"contacts":13},"Adneuris Site 001116","Plano","75093",{"type":51,"coordinates":160},[161,162],-96.69889,33.01984,{"lat":162,"lon":161},{"facility":165,"status":44,"city":166,"state":130,"zip":167,"country":48,"countryCode":49,"cosmosGeoPoint":168,"geoPoint":172,"contacts":13},"Adneuris Site 001111","San Antonio","78240",{"type":51,"coordinates":169},[170,171],-98.49363,29.42412,{"lat":171,"lon":170},{"facility":174,"status":44,"city":166,"state":130,"zip":167,"country":48,"countryCode":49,"cosmosGeoPoint":175,"geoPoint":177,"contacts":13},"Adneuris Site 001121",{"type":51,"coordinates":176},[170,171],{"lat":171,"lon":170},{"facility":179,"status":44,"city":180,"state":181,"zip":182,"country":48,"countryCode":49,"cosmosGeoPoint":183,"geoPoint":187,"contacts":13},"Adneuris Site 001101","Salt Lake City","Utah","84107",{"type":51,"coordinates":184},[185,186],-111.89105,40.76078,{"lat":186,"lon":185},{"type":189,"investigatorFullName":13,"investigatorTitle":13,"investigatorAffiliation":13,"oldNameTitle":13,"oldOrganization":13},"SPONSOR","100657920","phase-3-an-open-label-safety-and-efficacy-study-of-cebranopadol-in-participants-with-acute-pain-with-surgical-or-non-surgical-origin-100657920",false,"NCT07845071","An Open-Label, Safety and Efficacy Study of Cebranopadol in Participants With Acute Pain With Surgical or Non-Surgical Origin","An Open-Label, Single-Arm, Multiple-Dose, Phase 3 Safety and Efficacy Study of Cebranopadol in Participants With Moderate to Severe Acute Pain With Surgical or Non-Surgical Origin","Inclusion Criteria:\n\n* Adults 18 to 75 years of age.\n* Able to provide informed consent.\n* Experiencing moderate to severe acute pain related to: 1) An ambulatory surgical procedure expected to cause pain lasting at least 72 hours, or 2) A traumatic or non-traumatic musculoskeletal condition.\n* Have a pain score of at least 4 on a 0 to 10 pain rating scale before starting study treatment.\n* Willing and able to comply with study requirements\n\nExclusion Criteria:\n\n* Chronic pain condition that requires ongoing pain medication.\n* Significant medical or psychiatric condition that could affect participation or study results.\n* History of substance use disorder or misuse of alcohol or drugs.\n* Current use of medications that may interfere with the study drug or pain assessments.\n* Known allergy or intolerance to cebranopadol or permitted rescue pain medications.\n* Pregnant or breastfeeding.\n* Participation in another clinical trial or receipt of an investigational drug within the protocol-defined period before study entry.\n* Any condition that, in the investigator's opinion, would make participation unsafe or interfere with study assessments.","ALL","18 Years","75 Years",{"count":201,"type":202},160,"ESTIMATED","INTERVENTIONAL",[205],"PHASE3","The purpose of this study is to evaluate the safety and effectiveness of cebranopadol in treating acute pain.",[208],"Pain","2026-10-08",{"date":211,"type":212},"2026-10-13","ACTUAL",{"date":214,"type":212},"2026-09-22",{"date":216,"type":202},"2027-02",{"name":5,"class":6},15]